Diabetes Drug's cholesterol mystery: new study aims to unravel the why
NCT ID NCT03269058
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looks at why dapagliflozin, a diabetes drug, can raise 'bad' cholesterol levels. Researchers will track how the body makes and clears cholesterol in 28 adults with type 2 diabetes over 6 months. Half the participants will get dapagliflozin, the other half a placebo. The goal is to understand the problem so doctors can better manage cholesterol in these patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dapagliflozin
What this could lead to
If successful, this study could help doctors choose the right cholesterol-lowering drugs for people with type 2 diabetes who take dapagliflozin.
What could go wrong
This is a small, early-phase study with only 28 participants, so results may not apply to everyone. It aims to understand mechanisms, not prove a new treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Dijon Bourgogne
Dijon, 21079, France